Clinical Trial Search

Primary: The Number of Patients With no Fluid on OCT — 10 participants

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability — 0; 0; 1 Participants

Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read

Primary: Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) — 40; 7; 33 participants

Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters

Primary: Highest Tolerated Dose (HTD) of AGN-150998 — 4.2 mg

Primary: Macular Edema — 416 Microns

Primary: Change From Baseline at Month 1 in Central Subfield Thickness (CSFT) as Measured by Spectral Domain Ocular Coherence Tomography (SD-OCT) — -142.3; -181.6; -175.6; -174.9…

Primary: Visual Acuity (VA) — 8.51; 8.72; 8.67; 8.93 lines of VA

Primary: Summary of Adverse Events — 57; 16; 47; 4 participants

Primary: Development of Advanced AMD in People at Moderate to High Risk for Progression. — 493; 468; 507; 472 Eyes — p=<0.013

Primary: Change in Central Subfield Thickness on OCT From Baseline to Week 36 — -54; -.1 microns

Primary: Rate of Change in Area of Geographic Atrophy (GA), Based on Masked, Digital Grading of Fundus Photography by an External Reading Center, in the Study Eye at 12 Months…

Primary: Anatomic Response

Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02

Primary: Growth of Geographic Atrophy — 0.18; 0.19 millimeters

Primary: Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score — 7.2 letters

Primary: Monthly Rates of Anti-VEGF (Vascular Endothelial Growth Factor) Injections — 0.42; 0.83; 0.34; 0.83 Injections per Month

Primary: Percentage of Responders Based on CSFT and BCVA Outcomes at Day 14 and Day 28 — 70; 60; 80; 60 percentage of responders

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer

Primary: Change From Baseline Visual Acuity at 6 Months — 3.8 number of letters

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Mean Change in BCVA of ETDRS Letters From Baseline at 12 Months — 5.9; 7.6; 16.4 Letters

Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 — 7.03; 6.06; 5.89 scores on a scale — p=0.0009

Primary: Mean Reduction From Baseline in Central Subfield (CSF) Retinal Thickness at Week 4 — 514.2; 551.8; -12.1; 199.9 microns